Saturday 17 October 2026
Export NVCR’s income statement to Excel — free account
NovoCure Limited
NVCR Healthcare Medical Devices
NovoCure Limited’s revenue for fiscal 2025 (year ended December 2025) was $655.4 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 63.9%, free cash flow grew 105.7% and total debt rose 100.7%, each against the same quarter a year earlier.
14.07
0.34
−2.36%
Follow NVCR
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 865.20 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
4 | 5 | 1 | 4 | 4 | 6 | 7 | 4 | 4 | 4 |
P/S ratio |
2.20 | 5.31 | 3.01 | 13.22 | 14.51 | 35.33 | 23.32 | 12.39 | 10.15 | 8.10 |
Altman Z-Score |
0.43 | 1.26 | 0.68 | 6.39 | 6.87 | 18.95 | 18.50 | 6.77 | 5.06 | 0.21 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 754.04 | 132.55 | 207.47 | 507.85 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(2.29) | (1.67) | 1.21 | 3.23 | 3.73 | 4.63 | 1.27 | (1.37) | (2.55) | (2.45) |
Beneish M-Score |
(2.12) | (2.87) | (3.14) | (2.86) | (3.18) | (2.72) | (0.43) | (2.99) | (1.93) | (2.09) |
P/Operating CF |
(80.06) | (931.17) | (105.24) | (1,918.15) | 539.14 | 326.57 | 1,176.99 | 182.85 | (620.26) | (48.94) |
P/B ratio |
4.23 | 8.92 | 4.23 | 16.12 | 18.92 | 36.65 | 37.62 | 27.39 | 15.83 | 4.72 |
Price to Tangible BV |
4.23 | 8.92 | 4.23 | 16.12 | 18.92 | 36.65 | 37.62 | 27.39 | 15.83 | 4.72 |
EV/Sales |
1.80 | 3.91 | 2.33 | 12.47 | 13.81 | 34.47 | 22.82 | 12.00 | 9.66 | 6.61 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 398.05 | 1,492.64 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(24.04) | (89.82) | (16.21) | 217.82 | 89.29 | 171.87 | 301.11 | (1,595.53) | (51.59) | (5.09) |
EV/FCF |
(15.58) | (34.22) | (11.83) | 711.15 | 126.13 | 202.43 | 496.77 | (346.97) | (42.21) | (4.37) |
Quick Ratio |
2.71 | 1.42 | 5.56 | 6.82 | 7.36 | 8.56 | 4.82 | 4.63 | 4.44 | 6.41 |
Current Ratio |
2.90 | 1.46 | 5.78 | 7.00 | 7.53 | 8.80 | 5.10 | 4.98 | 4.88 | 7.10 |
Net Debt/EBITDA |
1.36 | 4.57 | 1.40 | 5.03 | 12.15 | (9.91) | (33.29) | 4.18 | 2.81 | 1.13 |
Debt/Assets |
29.43% | 9.45% | 49.63% | 47.46% | 49.34% | 40.87% | 31.17% | 43.93% | 36.69% | 34.11% |
Debt/Equity |
0.70 | 0.33 | 1.57 | 1.28 | 1.37 | 0.90 | 0.69 | 1.33 | 0.86 | 0.68 |
Asset Turnover |
0.64 | 0.51 | 0.44 | 0.46 | 0.49 | 0.65 | 0.86 | 0.82 | 0.65 | 0.28 |
Operating CF/Net income |
0.36 | 0.16 | 0.35 | (0.33) | (1.42) | 5.01 | (3.68) | 0.03 | 0.54 | 0.82 |
Capex/Depreciation |
3.09 | 2.97 | 2.24 | (2.35) | (1.81) | (1.21) | (1.67) | (0.67) | (0.93) | (3.04) |
Interest Coverage |
8.76 | 4.33 | 5.66 | 11.66 | (5.73) | 2.47 | (0.12) | (2.74) | (4.29) | (18.76) |
| (38.89%) | (46.67%) | (51.52%) | (21.73%) | (13.16%) | 5.71% | (4.38%) | (56.29%) | (48.19%) | (67.07%) | |
| (13.32%) | (14.13%) | (17.71%) | (7.94%) | (5.33%) | 2.59% | (1.77%) | (21.01%) | (22.53%) | (44.74%) | |
ROIC |
(80.34%) | 0.00% | (767.68%) | (152.27%) | (81.01%) | 36.29% | (1.46%) | (155.72%) | (96.51%) | (385.93%) |
Return on Tangible Assets |
(26.04%) | (38.09%) | (22.55%) | (9.27%) | (6.04%) | 2.18% | (1.95%) | (23.35%) | (28.95%) | (54.12%) |
Average Days of Receivables |
82.49 | 65.91 | 60.12 | 76.16 | 75.45 | 87.08 | 91.49 | 74.75 | 77.67 | 72.32 |
Research and Development Expense of Revenue |
34.26% | 34.64% | 43.79% | 38.32% | 37.62% | 26.70% | 22.49% | 20.39% | 21.52% | 50.03% |
Selling, General and Administrative Expense of Revenue |
63.74% | 70.87% | 76.74% | 56.97% | 49.19% | 45.60% | 52.55% | 60.92% | 69.28% | 133.26% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
16.00% | 26.44% | 22.70% | 19.89% | 17.74% | 15.32% | 14.92% | 16.06% | 15.32% | 26.71% |
Graham Net Nets |
0.13 | 0.07 | 0.16 | 0.05 | 0.04 | 0.02 | 0.02 | 0.03 | 0.05 | 0.18 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.61 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(9.44%) | (5.23%) | (13.54%) | (1.30%) | (0.75%) | 0.12% | (0.09%) | (2.09%) | (3.45%) | (19.75%) |
Free Cash Flow Yield |
(5.25%) | (2.15%) | (6.56%) | 0.13% | 0.75% | 0.48% | 0.20% | (0.28%) | (2.25%) | (18.65%) |
Revenue per Share |
5.88 | 5.61 | 4.79 | 5.14 | 5.17 | 4.90 | 3.61 | 2.70 | 2.00 | 0.97 |
Operating CF per Share |
(0.44) | (0.24) | (0.69) | 0.29 | 0.80 | 0.98 | 0.27 | (0.02) | (0.37) | (1.26) |
Capex per Share |
(0.24) | (0.40) | (0.25) | (0.20) | (0.23) | (0.15) | (0.11) | (0.07) | (0.08) | (0.21) |
Free Cash Flow per Share |
(0.68) | (0.64) | (0.94) | 0.09 | 0.57 | 0.83 | 0.17 | (0.09) | (0.46) | (1.46) |
Cash per Share |
4.10 | 8.92 | 8.58 | 9.27 | 9.07 | 8.46 | 3.38 | 2.70 | 2.09 | 2.57 |
Shareholders Equity per Share |
3.05 | 3.34 | 3.41 | 4.22 | 3.97 | 4.72 | 2.24 | 1.22 | 1.28 | 1.66 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.05 | 3.34 | 3.41 | 4.22 | 3.97 | 4.72 | 2.24 | 1.22 | 1.28 | 1.66 |
Free Cash Flow |
(75.68) | (69.22) | (100.43) | 9.43 | 58.59 | 84.18 | 16.14 | (8.58) | (40.50) | (125.26) |
Working Capital |
423.50 | 350.18 | 855.29 | 952.75 | 930.92 | 885.83 | 353.64 | 256.81 | 194.93 | 224.99 |
Capital Expenditures |
(26.65) | (42.85) | (27.09) | (21.36) | (24.17) | (14.97) | (10.48) | (6.71) | (7.37) | (17.66) |
Net Current Asset Value |
182.87 | 225.97 | 250.78 | 361.05 | 344.53 | 423.98 | 178.29 | 93.84 | 93.40 | 122.14 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 560.54 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.04 | 0.07 | 0.05 | 0.04 | 0.05 | 0.03 | 0.03 | 0.03 | 0.04 | 0.21 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 574.49 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(0.09) | (0.16) | (0.19) | 0.20 | 0.37 | 0.55 | 0.37 | 0.65 | 0.44 | 0.31 |
Cash ROIC |
(7.31%) | (4.81%) | (5.45%) | 0.48% | 3.07% | 4.78% | 2.32% | (1.68%) | (10.22%) | (27.32%) |
Accounts Receivable Turnover |
5.09 | 6.27 | 5.19 | 4.83 | 4.68 | 4.80 | 5.06 | 5.61 | 6.55 | 6.09 |
Accounts Payable Turnover |
1.47 | 1.38 | 1.43 | 1.46 | 1.82 | 2.35 | 2.78 | 3.65 | 3.13 | 2.64 |
Inventory Turnover |
4.38 | 3.75 | 3.80 | 4.27 | 4.43 | 4.17 | 3.83 | 3.59 | 2.34 | 2.36 |
Average Days of Payables |
267.35 | 279.60 | 268.57 | 270.72 | 230.67 | 183.86 | 152.11 | 121.78 | 112.93 | 144.76 |
Days of Inventory on Hand |
89.92 | 93.35 | 108.56 | 93.34 | 77.61 | 93.98 | 97.63 | 102.85 | 144.57 | 201.49 |
Average Receivables |
128.70 | 96.59 | 98.06 | 111.41 | 114.27 | 103.00 | 69.43 | 44.24 | 27.05 | 13.61 |
Average Payables |
113.66 | 99.74 | 89.79 | 78.90 | 63.12 | 45.29 | 31.82 | 21.96 | 17.78 | 17.56 |
Average Inventory |
38.10 | 36.62 | 33.76 | 26.90 | 25.92 | 25.56 | 23.13 | 22.29 | 23.79 | 19.57 |
Average Assets |
1,022.56 | 1,193.46 | 1,168.89 | 1,165.57 | 1,095.74 | 765.72 | 409.62 | 302.55 | 273.69 | 294.71 |
Average Common Equity |
350.32 | 361.34 | 401.83 | 425.83 | 443.51 | 347.16 | 165.02 | 112.91 | 127.95 | 196.58 |
Columns are period end dates